Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Validity of Intra-cortical Inhibition as a Biomarker of Cognitive Deficits in Schizophrenia and in Predicting the Efficacy of TMS Treatment

NCT05542212 is registered in ClinicalTrials.gov with Tongji University as lead sponsor.

NCT NCT05542212
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05542212 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Validity of Intra-cortical Inhibition as a Biomarker of Cognitive Deficits in Schizophrenia and in Predicting the Efficacy of TMS Treatment
Lead sponsor
Tongji University
Phase
Not applicable
Overall status
Unknown status
Start date
September 28, 2022
Completion date
February 29, 2024
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia